Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study

Trial Profile

Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Biotin (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MS-SPI
  • Sponsors MedDay Pharmaceuticals
  • Most Recent Events

    • 23 Mar 2017 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.
    • 25 May 2016 According to a MedDay Pharmaceuticals media release, extension phase data from this trial will be presented at the 2nd Congress of the European Academy of Neurology (EAN).
    • 21 Apr 2016 According to a MedDay media release, full results of this trial including the extension data were presented at the American Academy of Neurology Annual Meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top